Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novo Nordisk A/S (NVO) vs Stanley Black & Decker, Inc. (SWK) Price & Performance

Novo Nordisk A/STrade
Stanley Black & Decker, Inc.Trade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Stanley Black & Decker, Inc. — how do they compare? Novo Nordisk A/S trades at $44.72 (market cap $200.69B), while Stanley Black & Decker, Inc. trades at $91.6 (market cap $14.17B). The key difference: Novo Nordisk A/S is far larger — about 14.2× Stanley Black & Decker, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.98%). Which is the better fit depends on your goals.

NVOSWK
Market Cap
$200.69B$14.17B
Sector
Health
52-Week High
$63.98$104.00
52-Week Low
$35.29$62.12
Enterprise Value
$215.49B$18.33B
Dividend Yield
3.98%3.58%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.

NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.

Stanley Black & Decker, Inc.

Stanley Black & Decker (SWK) trades at $93.81, down 3.65% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with Q2 2026 EPS of $1.57 beating expectations of $1.21, and management has raised 2026 EPS guidance to $4.60-$5.45. Recent portfolio optimization includes the sale of Excel Industries to Bad Boy Mowers, focusing on core brands. Valuation metrics appear reasonable with P/E of 22.94 and P/S of 0.93, while analyst consensus price target sits at $98.50 with 43% buy ratings.

SWK presents a mixed outlook with strong earnings momentum and cost transformation benefits offset by bearish technical indicators. The stock offers value potential with upside to analyst targets and dividend income, but faces execution risks in margin expansion and industrial demand volatility. Near-term support at $90 provides a key level to watch amid current market weakness.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO

About Stanley Black & Decker, Inc.

Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.

Read more on SWK